Jobs / United States / Glaxosmithkline LLC

Glaxosmithkline LLC

Director, Oncology Translational Medicine, Clinical Biomarkers

4 Locations Posted today

Apply on employer site ↗ Tailor my CV first Source: Company careers site

Optional: we can tailor a CV and cover letter for this job from your real experience first (the first one is free).

Sponsorship verdict

Sponsorship possible

One solid signal, not two. Worth applying, and worth asking about sponsorship early.

  • Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first.
  • The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
  • No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
  • What Glaxosmithkline LLC paid sponsored hires in similar roles1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k.
  • Confirmed live todayWhen a source last listed this job as open.
Details and sources
Employer is on a government sponsor record
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
No salary bar for this route
H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
What Glaxosmithkline LLC paid sponsored hires in similar roles
1 certified filing for “Associate Director - Global Regulatory Affairs, Oncology” (Regulatory Affairs Managers) in WA: $154k–$154k, median $154k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).

US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).

A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.

About the role

For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage, UK. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. Director, Oncology Translational Medicine, Clinical Biomarkers   Job Purpose: The Director, Oncology Translational Medicine, Clinical Biomarkers is responsible for the development and effective implementation of biomarker and translational medicine strategies to support the clinical development of late-stage oncology assets. As a key member of a Clinical Matrix Team (CMT), the Clinical Biomarker Director will collaborate with the Clinical Biomarker Executive Director to establish clear decision-making criteria, define patient segmentation strategies, and integrate these into clinical development plans. You will leverage cutting-edge technologies and methodologies to discover and clinically validate biomarkers, ensuring the biomarker strategy is fully aligned with the clinical plan. This integration will optimise decision-making in drug development and enable the identification of the right patient populations for our medicines. Key responsibilities: • Collaborating closely with the Clinical Biomarker Executive Director to drive the design, alignment, and execution of clinical biomarker and translational medicine strategies focused on identifying predictive biomarkers that enable clinical success. • Validating and implementing biomarker strategies, including target engagement, pharmacodynamic, and proof-of-mechanism biomarkers, for clinical-phase programs to support patient stratification, dose selection, and enable clinical go/no-go decisions. • Participating in tumor-specific Biomarker Matrix teams, with responsibility for executing clinical biomarker strategies for late-stage oncology programs, while working closely with internal and external stakeholders, as well as disease area strategy teams. • Representing Translational Medicine at Clinical Development Matrix Teams (CMT) to establish biomarker-driven decision-making criteria and their seamless integration into clinical study designs, aligning with clinical study objectives • Supporting disease area strategies and translational objectives by defining biomarker priorities, areas of interest, and generating decision-enabling evidence packages informed by real-world datasets, internal and external data and partnerships (For e.g., research collaborations, KEE consultations). • Identifying cutting-edge science and technological advances to incorporate into biomarker strategies for guiding indication selection, patient enrichment, and combination strategies. • Overseeing and/or developing sample testing plans and delivering high-quality biomarker data packages to inform clinical development and regulatory strategies. • Managing effective relationships with clinical and scientific operations, diagnostics, medical science, medical affairs, regulatory, portfolio management, and commercial functions. • Supporting the expansion of mechanism and disease understanding to generate insights for indication expansion and scientific exchange as needed. • Defining and studying mechanisms of resistance to enable reverse translation, inform next-line strategies, support patient enrichment, and influence life cycle management of assets. • Contributing to the company’s scientific credibility through publications and presentations. Why You? Basic Qualifications: We are looking for professionals with the following required skills and experience: • Ph.D. or equivalent with 7+ years or M.Sc. with 10+ years of dru

Apply on employer site ↗